Evidence map›Paper›PMID 42653221›Full record

ReviewInternational journal of molecular sciences2026

Immunotherapy for Cancer: Current Advances and Future Directions.

Tanya Saxena, Shamsuz Zaman, Himanshu Dhanda, Sandeep Kumar Swain, Neetu Kushwaha, Manpreet Kaur, Raj Kamal, Sufian Zaheer, Pranay Tanwar, Neeraj Kumar and 3 more

Abstract readReview
In one paragraph

Review in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Tanya SaxenaNational Institute of Child Health Development Research, Indian Council of Medical Research, New Delhi 110029, India.ORCID 0009-0003-2172-4235
Shamsuz ZamanNational Institute of Child Health Development Research, Indian Council of Medical Research, New Delhi 110029, India.
Himanshu DhandaNational Institute of Child Health Development Research, Indian Council of Medical Research, New Delhi 110029, India.ORCID 0000-0001-6916-014X
Sandeep Kumar SwainNational Institute of Child Health Development Research, Indian Council of Medical Research, New Delhi 110029, India.ORCID 0000-0002-2782-6959
Neetu KushwahaNational Institute of Child Health Development Research, Indian Council of Medical Research, New Delhi 110029, India.
Manpreet KaurNational Institute of Child Health Development Research, Indian Council of Medical Research, New Delhi 110029, India.
Raj KamalNational Institute of Child Health Development Research, Indian Council of Medical Research, New Delhi 110029, India.
Sufian ZaheerDepartment of Pathology, Vardhman Mahavir Medical College and Safdarjung Hospital, New Delhi 110029, India.ORCID 0000-0002-8044-4327
Pranay TanwarLaboratory Oncology Unit, Dr. B.R. Ambedkar Institute Rotary Cancer Hospital, AIIMS, New Delhi 110029, India.ORCID 0000-0002-2357-976X
Neeraj KumarNational Institute of Child Health Development Research, Indian Council of Medical Research, New Delhi 110029, India.
Fouzia SirajCentre for Cancer Pathology, Indian Council of Medical Research, New Delhi 110029, India.ORCID 0000-0001-7643-7936
Bhavika RishiNational Institute of Child Health Development Research, Indian Council of Medical Research, New Delhi 110029, India.ORCID 0000-0002-5367-6050
Aroonima MisraNational Institute of Child Health Development Research, Indian Council of Medical Research, New Delhi 110029, India.ORCID 0000-0003-2884-3600

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immunotherapy delivers a fundamental shift in the treatment of multiple cancers, offering hope for patients with cancer. Unlike conventional therapies, it leverages the patient's immune system to precisely identify and destroy cancer cells. The remarkable journey of immunotherapy's has revolutionized oncology and paved the way for the development of modern immunotherapies. Several approaches are applied for immunotherapy, including immune checkpoint inhibitors, adoptive cell therapies, cancer vaccines, tumor microenvironment reprogramming, monoclonal antibodies, cytokine therapies, oncolytic virus therapy and combination strategies. Various immunotherapies are being used for different types of cancers like skin, lung, bladder, kidney, liver, breast and blood cancers. Despite providing an effective cancer treatment, immunotherapies face some challenges in their clinical implementation. To overcome these limitations, future directions emphasize the development of personalized and combination therapies, the incorporation of AI and a good delivery system. The main aim of this review is to give an overview of the journey of evolution, different approaches, limitations, advances and future development for immunotherapy in cancer treatment.

Indexed as

ImmunotherapyNeoplasmsAnimalsAntibodies, MonoclonalCancer VaccinesCombined Modality TherapyHumansImmune Checkpoint InhibitorsImmunotherapy, AdoptiveOncolytic VirotherapyTumor MicroenvironmentAntibodies, MonoclonalCancer VaccinesImmune Checkpoint Inhibitorsadoptive cell therapiescancer vaccinescytokine therapiesimmune checkpoint inhibitorsimmunotherapymonoclonal antibodiesoncolytic virus therapytumor microenvironment reprogramming

Identifiers

PMID42653221
PMCPMC13513274

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.